GFAP and Alzheimer disease: Likewise, for GFAP, there was no change in colocalisation with NNMT expression, with TOS (0.3 ± 0.015 vs. 0.19 ± 0.056, P = 0.06), M1 (59 ± 1.5% vs. 32.8 ± 13.9%, P = 0.06) and M2 (55.7 ± 1.2% vs. 35.9 ± 7.4%, P = 0.03) not significantly different in NDC and AD subjects (n = 3 for both).